Erschienen in:
01.10.2008 | Preclinical Study
DNA hypermethylation of PITX2 is a marker of poor prognosis in untreated lymph node-negative hormone receptor-positive breast cancer patients
verfasst von:
Inko Nimmrich, Anieta M. Sieuwerts, Marion E. Meijer-van Gelder, Ina Schwope, Joan Bolt-de Vries, Nadia Harbeck, Thomas Koenig, Oliver Hartmann, Antje Kluth, Dimo Dietrich, Viktor Magdolen, Henk Portengen, Maxime P. Look, Jan G. M. Klijn, Ralf Lesche, Manfred Schmitt, Sabine Maier, John A. Foekens, John W. M. Martens
Erschienen in:
Breast Cancer Research and Treatment
|
Ausgabe 3/2008
Einloggen, um Zugang zu erhalten
Abstract
Background In this study, we evaluated if PITX2 DNA methylation is a marker for disease recurrence in lymph node-negative (LNN), steroid hormone receptor-positive (HR+) breast cancer patients. In addition, we studied the association between PITX2 DNA methylation and PITX2 gene expression. Patients and methods
PITX2 DNA-methylation was measured in tumor tissue from 412 LNN/HR+ breast cancer patients who had not received any adjuvant systemic treatment. In addition, PITX2 DNA-methylation and mRNA expression was evaluated in 32 breast cancer cell lines. Results In univariate Cox regression analysis, DNA-methylation of PITX2 as a continuous variable was associated with early distant metastasis (HR = 1.71; P < 0.01) and poor overall survival (HR = 1.71; P < 0.01). In multivariate analysis together with the established prognostic factors age, tumor size and tumor grade, and steroid hormone receptor levels, both associations retained their significance (for MFS, HR = 1.74; P < 0.01; for OS, HR = 1.46; P = 0.02). In the breast cancer cell lines, PITX2 DNA methylation was inversely association with PITX2A and PITX2B mRNA expression (P < 0.01). Conclusions Hypermethylation of PITX2 is, in cell lines, negatively associated with PITX2 mRNA expression and, in clinical specimens, positively associated with breast cancer disease progression.